4.7 Article

211At-labeled agents for alpha-immunotherapy: On the in vivo stability of astatine-agent bonds

Journal

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 116, Issue -, Pages 156-164

Publisher

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2016.03.082

Keywords

Targeted radionuclide therapy; Astatine; Density functional theory; Bond enthalpy; In vivo stability

Funding

  1. French National Agency for Research [ANR-2010-BLAN-0807]
  2. Investissements d'Avenir [ANR-11-EQPX-0004, ANR-11-LABX-0018]
  3. GENCI-CINES/IDRIS [2015-c2015085117]

Ask authors/readers for more resources

The application of At-211 to targeted cancer therapy is currently hindered by the rapid deastatination that occurs in vivo. As the deastatination mechanism is unknown, we tackled this issue from the viewpoint of the intrinsic properties of At-involving chemical bonds. An apparent correlation has been evidenced between in vivo stability of At-211-labeled compounds and the At-R (R = C, B) bond enthalpies obtained from relativistic quantum mechanical calculations. Furthermore, we highlight important differences in the nature of the At-C and At-B bonds of interest, e.g. the opposite signs of the effective astatine charges, which implies different stabilities with respect to the biological medium. Beyond their practical use for rationalizing the labeling protocols used for At-211, the proposed computational approach can readily be used to investigate bioactive molecules labeled with other heavy radionuclides. (C) 2016 Elsevier Masson SAS. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available